Skip to content

CATUG Inc and MxT Biotech Announce Strategic Partnership Towards Gene Editing and Cell Therapy

CAMBRIDGE, Massachusetts and SEOUL, South Korea, January 17, 2024 – CATUG Inc. (CATUG) and MxT Biotech (MxT) have signed a Memorandum of Understanding (MOU) to form a strategic partnership aimed at advancing research and development in the field of cell engineering. Together, CATUG, a leading CRDMO in nucleic acids (DNA, mRNA) and LNP technology, and MxT, renowned for its innovative non-viral gene delivery platform, Hydroporator®, will propel the current state-of-the-art in cell transfection and intracellular delivery technologies.
Aram Chung, the founder and CEO of MxT Biotech, expressed enthusiasm about the collaboration, stating, "We are thrilled to publicly announce this collaboration, confident that it will create synergies benefiting both companies. CATUG's unique and high quality nucleic acids will be showcased as effective resources, while MxT Biotech will demonstrate the versatility of its Hydroporator® platform in delivering diverse nanomaterials." Dr. Chung further emphasized the transformative nature of this collaboration, emphasizing its potential to democratize non-viral gene delivery systems within the field of cell engineering.
Lin Jin, co-founder and CTO of CATUG, echoed the sentiment, stating, "We are excited to embark on this transformative journey with MxT. This collaboration aligns with our commitment to advancing the field of gene editing and cell engineering with non-viral delivery approaches. MxT’s Hydroporator® platform will further demonstrate the cell engineering efficiency with CATUG’s high-purity payload materials to unlock new possibilities.“ Dr. Jin further expressed enthusiasm about this synergetic collaboration to deliver cutting-edge solutions and potential impact on the next generation of gene and cell therapy.
CATUG and MxT are confident that through this partnership, the two companies will pool their expertise to elevate gene editing and cell therapy standards, as well as make significant contributions to the entire gene editing and cell therapy industry.
CATUG is a specialized Contract Research and Development Manufacturing Organization (CRDMO) for one-stop solution in nucleic acid-based therapeutics through its leading DNA, RNA, LNP and analytical platforms. With strong expertise and know-how, CATUG aims to provide customized solutions in the life cycle of mRNA therapeutics, gene editing and GCT development. For more detailed information, please visit
About MxT Biotech
MxT Biotech stands at the forefront of biotechnology, driving advancements in cancer immunotherapy, cellular engineering, and genome editing. The company's patented non-viral gene delivery platform, Hydroporator®, serves as a pioneering force in the industry. For more detailed information, please visit
CATUG Contact:
Lin Jin, Ph.D.